Bupropion very rarely causes tardive dyskinesia. The risk is extremely low compared to antipsychotic medications, which are the drugs most commonly associated with this condition. However, at least one documented case exists of tardive dyskinesia developing in a patient taking bupropion alone, with no prior exposure to antipsychotics, and the FDA’s prescribing label lists both dyskinesia and “unmasking tardive dyskinesia” as postmarketing adverse events.
What the Evidence Actually Shows
Tardive dyskinesia (TD) is a movement disorder involving repetitive, involuntary motions, most often of the tongue, lips, and jaw. It’s overwhelmingly linked to antipsychotic drugs that block dopamine receptors. Bupropion works differently: instead of blocking dopamine, it increases dopamine activity by preventing the brain from reabsorbing it. That mechanism makes TD theoretically unlikely, which is why it’s so rarely reported.
A large analysis of the World Health Organization’s global drug safety database compared movement disorder reports across antidepressant classes. Bupropion’s adjusted reporting odds ratio for tardive dyskinesia was 0.83, meaning it was actually reported less often than the average antidepressant. By comparison, venlafaxine had a ratio of 1.35 and SSRIs as a class came in at 1.21, both statistically significant. Bupropion’s number did not reach statistical significance, suggesting any association is weak at best.
That said, the signal isn’t zero. The FDA label for Wellbutrin XL lists dyskinesia, dystonia, extrapyramidal syndrome, and unmasking of tardive dyskinesia in its postmarketing reports. Because these come from voluntary reporting rather than controlled trials, there are no reliable incidence rates. Tremor, a more common but distinct movement side effect, does have clinical trial data: it affected about 3 to 6% of patients in depression trials versus 1% on placebo.
The Key Case Report
The most notable documented case, published in Clinical Psychopharmacology and Neuroscience, involved a 46-year-old man with major depression and no history of antipsychotic use. He started bupropion XL at 150 mg daily, and after a month his dose was increased to 300 mg. Two months after the dose increase, he developed repetitive involuntary movements of his tongue and lips, the hallmark pattern of tardive dyskinesia.
His doctors ran a thorough workup: brain imaging, blood tests, neurological exam. Everything came back normal. He had no family history of neurological disease and had never taken an antipsychotic. When his dose was reduced back to 150 mg, the movements persisted. Bupropion was then stopped entirely, and his involuntary movements resolved five months later. Using a standardized scale for rating whether a drug likely caused a side effect (the Naranjo scale), clinicians scored the reaction at 7 out of 13, placing it in the “probable” category.
This was described as the first case report of tardive dyskinesia from bupropion in a patient with no prior antipsychotic exposure. That distinction matters: in other reported cases of bupropion-linked movement problems, patients had often taken antipsychotics in the past, making it hard to separate which drug was responsible.
Why Bupropion Could Theoretically Cause TD
Bupropion and its active breakdown products bind to dopamine transporters in the striatum, a brain region that controls movement. At therapeutic doses, this binding increases dopamine levels in the same circuits that antipsychotics disrupt. Positron emission tomography (PET) scans have confirmed that standard oral doses of bupropion effectively occupy these transporters in living humans.
The paradox is that TD is classically caused by drugs that reduce dopamine signaling, not drugs that enhance it. One hypothesis is that chronically elevated dopamine from bupropion could cause dopamine receptors to become hypersensitive over time, similar to what happens when antipsychotics are used long-term. This receptor hypersensitivity is one of the leading theories behind TD in general. Another possibility is that bupropion unmasks existing TD that was previously suppressed, particularly in patients who have taken antipsychotics in the past.
How TD Differs From Other Movement Side Effects
If you’re taking bupropion and notice unusual movements, it helps to know what you’re looking at. Tremor is the most common movement-related side effect of bupropion, showing up in clinical trials at rates of 3 to 6%. Tremor is a rhythmic shaking, usually of the hands, and it typically appears early in treatment.
Tardive dyskinesia looks different. It involves repetitive, purposeless movements concentrated around the mouth: lip smacking, tongue protrusion, chewing motions. These movements are involuntary, meaning you can’t control them, though they often worsen with anxiety or stress. TD also tends to appear after weeks or months of treatment rather than in the first few days.
Akathisia is another movement-related side effect sometimes reported with antidepressants. It feels like an intense inner restlessness, a compelling need to move, pace, or shift your weight. Unlike TD, akathisia is driven by subjective discomfort rather than involuntary muscle movements. You feel like you can’t sit still, rather than watching your body move on its own.
Who Might Be at Higher Risk
Because bupropion-associated TD is so rare, there isn’t enough data to build a reliable risk profile specific to this drug. General risk factors for drug-induced movement disorders include older age, female sex, higher doses of the triggering medication, and longer duration of treatment. Some research on bupropion-induced dystonia (a related but distinct movement problem involving sustained muscle contractions) has noted cases in younger males, particularly when bupropion was combined with an SSRI. The interaction between serotonin-boosting drugs and bupropion’s dopamine effects could potentially amplify movement-related side effects.
People with Parkinson’s disease or other conditions affecting the brain’s dopamine system may also be more vulnerable. One case report documented severe dystonia in an elderly woman with Parkinson’s disease who was started on bupropion for depression. Her existing dopamine imbalance likely made her more susceptible to movement side effects.
What Happens if TD Develops
In the documented bupropion case, the timeline from stopping the drug to full resolution of symptoms was about five months. That’s consistent with how TD from other drugs sometimes behaves: it doesn’t resolve immediately when the medication is withdrawn, but it can gradually improve over weeks to months. In some cases of TD caused by antipsychotics, the movements become permanent, but this outcome has not been reported with bupropion specifically.
The key practical point is that TD caused by bupropion appears to be reversible based on existing evidence, likely because bupropion’s effect on dopamine is milder and mechanistically different from antipsychotics. If you notice repetitive involuntary movements of your face, tongue, or jaw while taking bupropion, bringing this to your prescriber’s attention promptly gives the best chance of full recovery.